Maze Therapeutics公布Mze782一期临床试验积极的首次人体试验结果,证实了这一强效口服Slc6a19抑制剂的作用机制,有望治疗苯丙酮尿症和慢性肾病
Maze Therapeutics公布Mze782一期临床试验积极的首次人体试验结果,证实了这一强效口服Slc6a19抑制剂的作用机制,有望治疗苯丙酮尿症和慢性肾病
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.